神経痛治療市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年、治療法別、適応症別、流通チャネル別、地域別、競合

神経痛治療の世界市場は、2022年に10億1,165万米ドルと評価され、2028年までのCAGRは11.80%で、予測期間中に目覚ましい成長を予測しています。

2023年の世界神経痛治療市場は、神経痛に関連する症状の診断と管理における著しい成長と進歩が特徴です。神経痛とは、神経経路に沿った刺すような、または焼けるような激しい痛みを指し、多くの場合、神経の刺激または損傷によって引き起こされます。

主な市場促進要因

神経痛関連疾患の有病率の上昇

神経痛は、神経経路に沿った耐え難い痛みを特徴とする疾患で、世界中で数百万人が罹患し、生活の質に大きな影響を及ぼしています。神経痛には三叉神経痛、帯状疱疹後神経痛、糖尿病性神経障害などさまざまな病態があるが、共通の傾向として、神経痛関連疾患の有病率が上昇していることが挙げられます。この有病率の増加は、医療業界にとって大きな課題であると同時にチャンスでもあります。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 神経痛治療の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別（薬物療法、手術療法）
  • 適応症別（糖尿病性神経障害、肋間神経痛、後頭神経痛、末梢神経痛、帯状疱疹後神経痛、三叉神経痛）
  • 流通チャネル別（病院薬局、オンライン薬局、小売薬局）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • 治療法別
  • 適応症別
  • 販売チャネル別
  • 地域別

第6章 北米の神経痛治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別
  • 適応症別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の神経痛治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別
  • 適応症別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋の神経痛治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別
  • 適応症別
  • 流通チャネル別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の神経痛治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別
  • 適応症別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの神経痛治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 治療法別
  • 適応症別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Neuralgia Treatment Market has valued at USD 1011.65 million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 11.80% through 2028. The Global Neuralgia Treatment Market in 2023 is characterized by significant growth and advancements in the diagnosis and management of neuralgia-related conditions. Neuralgia refers to severe, stabbing, or burning pain along a nerve pathway, often caused by irritation or damage to the nerves.

Key Market Drivers

Rising Prevalence of Neuralgia-Related Conditions

Neuralgia, a condition characterized by excruciating pain along nerve pathways, affects millions of individuals worldwide, significantly impacting their quality of life. While neuralgia encompasses various forms, including trigeminal neuralgia, postherpetic neuralgia, and diabetic neuropathy, one common trend is the rising prevalence of neuralgia-related conditions. This growing prevalence represents both a significant challenge and an opportunity for the healthcare industry.

As the global population ages, there is a higher likelihood of individuals developing neuralgia-related disorders. Conditions such as trigeminal neuralgia and diabetic neuropathy are more common in older adults, and the aging demographic contributes to a growing patient pool. The worldwide increase in diabetes cases is a major driver of diabetic neuropathy, a painful neuralgia-related condition. With diabetes becoming a global epidemic, the number of patients at risk for diabetic neuropathy is escalating. Postherpetic neuralgia often follows a bout of shingles (herpes zoster), and the incidence of shingles is also on the rise. This trend is attributed to factors such as reduced immunity in older adults and the herpes zoster vaccine's limited reach.

The growing number of individuals afflicted by neuralgia-related conditions naturally expands the patient pool for neuralgia treatments. A larger market size presents significant opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. The surge in neuralgia cases fuels demand for innovative and more effective treatment options. This creates an incentive for research and development in the field, driving the creation of new drugs, medical devices, and therapies. As the prevalence of neuralgia-related conditions increases, there is a growing emphasis on personalized medicine. Tailoring treatments to individual patient needs, taking into account factors like genetics and pain severity, becomes a priority, leading to the development of targeted therapies. To meet the rising demand for neuralgia treatment, healthcare systems are likely to expand their infrastructure, including specialized pain management clinics and telemedicine services, enhancing patient access to care. The increasing prevalence of neuralgia-related disorders prompts greater public awareness. With more people informed about these conditions, patients are likely to seek medical attention earlier, fostering early diagnosis and prompt treatment.

Technological Advancements in Diagnosis and Treatment

Technological advancements have permeated every facet of healthcare, leading to groundbreaking developments in the diagnosis and treatment of various medical conditions. The field of neuralgia treatment is no exception. Neuralgia, characterized by excruciating pain along nerve pathways, has seen a significant transformation in how it is diagnosed and managed, thanks to innovations in medical technology.

High-resolution imaging technologies, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, have become instrumental in the diagnosis of neuralgia-related conditions. These technologies provide detailed views of neural structures, allowing healthcare providers to identify the source of nerve compression or damage more accurately. Electromyography (EMG) and nerve conduction studies (NCS) have become invaluable tools for diagnosing neuralgia. They help assess nerve function, pinpoint areas of dysfunction, and guide treatment decisions. Telemedicine platforms have facilitated remote consultations and diagnoses, making it easier for patients to access specialized care regardless of their location. This technology enables healthcare providers to offer timely assessments, enhancing the speed at which neuralgia conditions are diagnosed and addressed.

Technological advancements have paved the way for minimally invasive procedures to manage neuralgia effectively. Techniques such as nerve blocks, cryoablation, and radiofrequency ablation allow targeted treatment of nerve pain with minimal tissue disruption, reducing patient discomfort and recovery times. Implantable spinal cord stimulators deliver electrical pulses to the spinal cord, interrupting pain signals to the brain. Technological improvements in these devices have enhanced their efficacy, making them a preferred choice for many patients suffering from chronic neuralgia. Gamma Knife radiosurgery utilizes highly focused radiation beams to target and destroy abnormal nerve tissue. Technological advancements have made this non-invasive procedure even more precise and effective in treating neuralgia. Technological tools like high-throughput screening and computational modeling have accelerated drug discovery, leading to the development of new and more effective medications for neuralgia management. These medications can provide relief while minimizing side effects.

The incorporation of technological advancements has broadened the spectrum of treatment options available to patients. This diversity not only improves patient outcomes but also attracts a broader patient base, boosting market growth. Technological innovations lead to treatments with greater efficacy and fewer side effects. This enhances patient satisfaction and encourages more individuals to seek treatment, further expanding the market. Minimally invasive procedures and targeted therapies often result in shorter hospital stays and faster recoveries. This can reduce healthcare costs, making treatment more accessible to a broader range of patients. Telemedicine and remote monitoring technologies enable patients to access specialized neuralgia care globally. This global reach opens new markets and opportunities for healthcare providers and manufacturers. The promise of technological advancements in neuralgia treatment attracts investments in research and development, driving further innovation and expansion within the market.

Pharmaceutical Innovations

Pharmaceutical innovations have long been at the forefront of the medical field, driving advancements in treatments for a wide range of conditions. In recent years, the field of neuralgia treatment has seen significant developments thanks to the relentless pursuit of new and improved medications. Neuralgia, characterized by intense, debilitating pain along nerve pathways, is a complex condition that affects millions of people globally.

Pharmaceutical companies are investing heavily in research and development to create medications tailored specifically to neuralgia-related conditions. These targeted therapies aim to address the underlying causes of neuralgia, providing more effective pain relief and improved patient outcomes. Innovative drug delivery systems, such as long-acting formulations and patches, have been developed to enhance patient compliance and convenience. These systems provide a steady release of medication over time, reducing the need for frequent dosing. Newer medications are designed with a focus on minimizing side effects, making them more tolerable for patients. This not only improves patient comfort but also increases adherence to treatment plans. Pharmaceutical innovations have led to the development of combination therapies that synergistically target different aspects of neuralgia. Combining multiple drugs can provide superior pain relief compared to single-agent therapies.

The primary goal of pharmaceutical innovations in neuralgia treatment is to provide more effective pain management. Medications are designed to block or modulate pain signals, offering relief even in severe cases. Some new drugs have a quicker onset of action, providing rapid relief to patients in acute pain. This is particularly valuable in emergency situations or when immediate relief is required. Patient needs and preferences are increasingly considered in drug development. Medications are being designed with patient comfort and convenience in mind, promoting adherence to treatment plans.

The introduction of innovative pharmaceuticals broadens the range of treatment options available to patients. This expanded therapeutic arsenal can attract a larger patient base, driving market growth. Pharmaceutical innovations in neuralgia treatment attract investments in research and development. These investments stimulate further breakthroughs, leading to the creation of more effective medications. Medications that provide better pain relief can reduce healthcare costs by minimizing hospitalizations and the need for more invasive treatments. This cost-effectiveness can make neuralgia treatment more accessible to a broader patient population. Pharmaceutical companies often have a global reach, making innovative medications accessible to patients around the world. This global expansion opens new markets and opportunities for growth.

Awareness and Education

Neuralgia, characterized by intense and often debilitating pain along nerve pathways, can significantly diminish the quality of life for those affected. As the prevalence of neuralgia-related conditions continues to rise, increasing awareness and education about these disorders have become imperative.

Increasing public awareness about neuralgia-related conditions can help individuals recognize their symptoms and seek appropriate medical care. This can lead to earlier diagnoses and more effective treatment, ultimately improving patient outcomes. Healthcare providers play a pivotal role in diagnosing and managing neuralgia. Medical education and training programs should include comprehensive coverage of neuralgia-related conditions, ensuring that healthcare professionals are well-equipped to identify and treat these disorders. Establishing specialized pain management clinics or centers focused on neuralgia-related conditions can centralize expertise and provide a dedicated space for patient education and treatment.

Educating patients about the signs and symptoms of neuralgia empowers them to seek medical attention at the earliest signs of the condition. Early intervention is often associated with better treatment outcomes. Informed patients are better equipped to discuss treatment options with their healthcare providers and make decisions that align with their preferences and values. Education can help patients understand the full spectrum of treatment choices available to them. Awareness campaigns can help reduce the stigma associated with neuralgia-related conditions, encouraging individuals to seek help without fear of judgment or misunderstanding.

As awareness grows, more individuals are likely to seek treatment for neuralgia-related conditions, leading to an increased demand for therapies, medications, and medical devices. This expanded patient base can drive market growth. Greater awareness can attract investments in research and development for new treatments and technologies. Pharmaceutical companies and medical device manufacturers are more likely to allocate resources to address conditions with a higher profile. An educated patient population can drive the establishment of specialized clinics and healthcare providers focused on neuralgia treatment. These entities can collaborate with pharmaceutical companies and contribute to market growth.

Key Market Challenges

Underdiagnosis and Misdiagnosis

A major challenge is the underdiagnosis and misdiagnosis of neuralgia-related conditions. Many individuals endure their symptoms without seeking medical attention, often because they are unaware of their condition or its severity. Misdiagnosis can lead to inappropriate treatments and delays in receiving proper care.

Limited Treatment Options

While there have been notable advancements in neuralgia treatment, there remains a need for more diverse and effective therapeutic options. Existing treatments, such as medications and minimally invasive procedures, may not provide sufficient relief for all patients, leaving a gap in addressing severe cases.

Key Market Trends

Advanced Diagnostic Tools

Early and accurate diagnosis is crucial for effective neuralgia treatment. The development of more sophisticated diagnostic tools, such as high-resolution imaging, nerve conduction studies, and genetic testing, will enable healthcare professionals to identify neuralgia-related conditions with greater precision. Timely diagnosis will lead to more targeted treatments.

Neuromodulation Techniques

Neuromodulation therapies, including spinal cord stimulation, dorsal root ganglion stimulation, and peripheral nerve stimulation, are gaining popularity as effective treatments for neuralgia. Upcoming trends in neuromodulation include improved device designs, wireless technology, and patient-controlled settings, enhancing the precision and comfort of these therapies.

Segmental Insights

Treatment Insights

Based on the category of Treatment, the surgical treatment category dominated the market in 2022 and is expected to experience substantial expansion throughout the projected period. This growth is primarily attributed to the increasing awareness of diverse treatment alternatives and the substantial expenses associated with surgical procedures. To provide some context, the typical costs for neuralgia surgery stand at approximately USD 40,000 for microvascular decompression, USD 38,000 for stereotactic radiosurgery, and USD 3,900 for percutaneous stereotactic radiofrequency rhizotomy.

Indication Insights

Intercostal Neuralgia is poised for significant growth in the Global Neuralgia Treatment Market in the forecast years due to several key factors. Firstly, a growing aging population worldwide is more susceptible to neuralgia conditions, including Intercostal Neuralgia, thereby increasing the patient pool. Additionally, advancements in diagnostic techniques and increasing awareness among patients regarding available treatment options are expected to drive demand for interventions targeting Intercostal Neuralgia. Furthermore, the ongoing development of innovative therapies and drugs specifically designed for neuralgia treatment, along with a surge in healthcare expenditure, is likely to contribute to the expansion of the Intercostal Neuralgia treatment segment within the market. As a result, the forecast years hold promising prospects for the growth of Intercostal Neuralgia within the broader Neuralgia Treatment Market.

Regional Insights

In 2022, North America held a dominant position in the market and is projected to experience substantial growth in the coming forecast period. The urinary drainage bags market in North America is primarily being propelled by the increasing occurrence of neuralgia and the presence of key industry players in the region. Additionally, the growing awareness surrounding various treatment alternatives is expected to further stimulate market growth in North America.

Conversely, the Asia Pacific region is expected to witness the most rapid growth rate during the forecast period. This growth can be attributed to the escalating prevalence of diabetes and the expanding elderly population in the area. For instance, the adult diabetes prevalence rate in India stands at 8.9%, a substantial figure that is poised to drive the market for neuralgia treatment.

Key Market Players

GSK PLC

Pfizer Inc

Novartis AG

Biogen Inc

Cadila Pharmaceuticals Ltd

Lundbeck Pharmaceuticals Ltd

Report Scope:

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuralgia Treatment Market, By Treatment:

• Drug-Based
• Surgery

Neuralgia Treatment Market, By Indication:

• Diabetic Neuropathy
• Intercostal Neuralgia
• Occipital Neuralgia
• Peripheral Neuralgia
• Postherpetic Neuralgia
• Trigeminal Neuralgia

Neuralgia Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Neuralgia Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Neuralgia Treatment Market.

Available Customizations:

• Global Neuralgia Treatment market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neuralgia Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment (Drug-Based, Surgery)
  • 5.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Treatment
  • 5.3.2. By Indication
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Neuralgia Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment (Drug-Based, Surgery)
  • 6.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Neuralgia Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Neuralgia Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Neuralgia Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Neuralgia Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment (Drug-Based, Surgery)
  • 7.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 7.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Neuralgia Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Neuralgia Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. France Neuralgia Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Neuralgia Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Neuralgia Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Neuralgia Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment (Drug-Based, Surgery)
  • 8.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 8.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Neuralgia Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Japan Neuralgia Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. India Neuralgia Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Australia Neuralgia Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. South Korea Neuralgia Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. South America Neuralgia Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment (Drug-Based, Surgery)
  • 9.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 9.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Neuralgia Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Neuralgia Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Neuralgia Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Neuralgia Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment (Drug-Based, Surgery)
  • 10.2.2. By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia)
  • 10.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Neuralgia Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Neuralgia Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Neuralgia Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel
  • 10.3.4. Kuwait Neuralgia Treatment Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Treatment
      • 10.3.4.2.2. By Indication
      • 10.3.4.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. GSK PLC
  • 14.6.2. Pfizer Inc
  • 14.6.3. Novartis AG
  • 14.6.4. Biogen Inc
  • 14.6.5. Cadila Pharmaceuticals Ltd
  • 14.6.6. Lundbeck Pharmaceuticals Ltd

15. Strategic Recommendations

16. About Us & Disclaimer